Background Clopidogrel/aspirin antiplatelet therapy is routinely administered 7 to 10 days prior to pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600 mg loading dose of clopidogrel 24 hours before PED treatment.
Methods We performed a retrospective cohort study involving patients treated with pipeline from October 2010 to May 2016. They were divided into two groups: 39.7%(n=158) patients were dispensed a loading dose of 650 mg of aspirin plus at least 600 mg of clopidogrel 24 hours preceding PED deployment; 60.3%(n=240) received 81–325 mg of aspirin daily for 10 days with 75 mg of clopidogrel daily pre-procedurally. The mean follow-up was 15.8 months (SD=12.4 months). modified Rankin Scale (mRS) was registered before the discharge and at each follow-up visit. To control confounding we used multivariable logistic regression and propensity score conditioning.
Results Of 398 patients, the proportion of female patients was ≈16.5% (41/240) in both groups and shared the same mean of age ≈56.46 years. Similarly, ≈12.2% (mean=0.09; SD=0.30) had a subarachnoid hemorrhage. 92% (mean=0.29; SD=0.70) from the pre-treatment group and 85.7%(mean=0.44; SD=0.91) of the bolus group had a mRS&It=2. In a multivariate analysis, bolus did not affect the mRS score, p=0.24. 7 patients had a long-term recurrence: 2 (0.83%; mean=0.01; SD=0.10) from the pre-treatment group. In a multivariable logistic regression, bolus was not associated with a long-term recurrence rate (OR, 1.91; CI95%, 0.27–13.50; p=0.52) neither with thromboembolic accidents (OR, 0.99; CI 95%, 0.96–1.03; p=0.83) nor with hemorrhagic events (OR, 1.00; CI95%, 0.97–1.03; p=0.99). 3 patients were announced dead: (1) receiving bolus had an acute SAH. The mean mortality rate was parallel in both groups ≈0.25(SD=0.16). Bolus was not associated with mortality (OR, 1.11; CI95%, 0.26–4.65; p=0.89). The same associations were present in propensity score adjusted models.
Conclusion In a cohort receiving PED, 600 mg loading dose of clopidogrel should be safe and efficacious in those off the standard protocol or showing and It30% platelet inhibition before treatment.
Disclosures E. Atallah: None. K. Bekelis: None. S. Tjoumakaris: None. R. Rosenwasser: None. P. Jabbour: None.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.